Agentix CORP

Agentix Corp. reports significant financial distress with a substantial doubt about its ability to continue as a going concern, marked by increasing net losses and negative working capital.

Agentix Corp. reported increased net losses and negative operating cash flow, raising substantial doubt about its ability to continue as a going concern.

Agentix Corp. reported increased net losses and critically low cash for Q1 2026, raising substantial doubt about its ability to continue as a going concern.

Agentix Corp.'s Q3 2025 report reveals ongoing losses and negative cash flow, raising substantial doubt about the company's ability to continue as a going concern.

Agentix Corp.'s Q2 2024 report shows a decrease in operating expenses but highlights ongoing concerns about the company's ability to continue as a going concern due to accumulated deficits and insufficient cash.

Agentix Corp.'s Q1 2025 report reveals a net loss and continued concerns about the company's ability to operate as a going concern due to insufficient cash and significant liabilities.

A clinical-stage biotechnology company developing metabolic disease treatments reports no revenue, increasing losses, and significant doubt about its ability to continue operations without substantial new financing.

Agentix Corp.'s annual report on Form 10-K reveals a focus on developing metabolic disease treatments, ongoing financial challenges, and a lack of revenue generation.